SCHEMBL23138124

SCHEMBL23138124

CCOC(=O)[C@H](O)COC1CCOCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 2/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
GAA P10253 1/20 0.36
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
RECQL P46063 1/20 0.35
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HTR5A P47898 1/20 0.33
KAT2B Q92831 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20702949 0.80 PGK1 (0.41) PRMT5WDR77L3MBTL1HTR5AKAT2B
SCHEMBL20702948 0.80 PGK1 (0.41) PRMT5WDR77L3MBTL1HTR5AKAT2B
SCHEMBL29115625 0.79 ALDH1A1 (0.35) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL29115627 0.79 ALDH1A1 (0.35) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL5425764 0.77 ALDH1A1 (0.35) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL3254867 0.75 TSHR (0.42) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL8333187 0.75 ALDH1A1 (0.42) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL31662531 0.72 PIK3CD (0.35) KMT2ACYP3A4CYP2C19PRMT5WDR77
SCHEMBL20713608 0.72 TSHR (0.47) ALDH1A1LMNARAB9ATSHRGAA
SCHEMBL24547509 0.72 PRMT5 (0.36) KMT2APRMT5WDR77L3MBTL1HTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2025-07-10 US disclosed
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NodThera Limited (GB) 2025-03-11 US disclosed
EP-3661921-B1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NODTHERA LTD (GB) 2023-10-18 EP disclosed
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2021-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NLRP3, NOD1, NLRP1 ALDH1A1 961/4885LMNA 1234/4885KMT2A 4593/4885
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 ALDH1A1 961/4885LMNA 1234/4885KMT2A 4593/4885
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 ALDH1A1 961/4885LMNA 1234/4885KMT2A 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.